Ardelyx (STU:41X) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:41X Ardelyx Inc STU:41X
71 GF Score
Price €4.29
GF Value €9.03
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Ardelyx SpecialCharges?

Special Charges only applies to banks.

STU:41X
71GF Score
Ardelyx Inc STU:41X
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ardelyx (STU:41X) Overvalued in 2026?

Based on GuruFocus' analysis, Ardelyx stock appears to be undervalued. The current stock price of €4.29 is trading 52.5% below its estimated GF Value™ of €9.03. GuruFocus considers Ardelyx to be Possible Value Trap.

Key valuation signals for STU:41X:

  • SpecialCharges:
  • GF Value™: €9.03 vs. price of €4.29 (52.5% below fair value)
  • GF Score™: 71/100 with 6 warning signs

No single metric tells the full story. See the STU:41X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ardelyx Business Description

Other Exchanges ARDX:USAARDX:Mexico
Address 400 Fifth Avenue, Suite 210, Waltham, MA, USA, 02451
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
71GF Score

Get the complete analysis for STU:41X

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.29
Price
€9.03
GF Value